Prognostic markers for survival in patients with pancreatic ductal adenocarcinoma
03/2021
MUDr. Michal Eiď1; MUDr. Štěpan Tuček, Ph.D.1; MUDr. Lumír Kunovský, Ph.D.2,3
1 Interní hematologická a onkologická klinika LF MU a FN Brno
2 Interní gastroenterologická klinika LF MU a FN Brno
3 Chirurgická klinika LF MU a FN Brno
SUMMARY
Incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing, and mortality remains high. It has already been proven that PDAC is not one uniform disease. It is considered a very heterogeneous malignancy. Despite a growing knowledge, no breakthrough therapy leading to long-term survival has been implemented into the clinical practice during last 30 years. An exception is an intensive triplet chemotherapy regimen with 5-fluorouracil, oxaliplatin and irinotecan (FOLFIRINOX), that leads to median overall survival 54,4 months and median disease free survival 21,6 months in adjuvant setting. It should be noted that in this PRODIGE 24 trial, inclusion criteria were strict and study population was selected. This intensive chemotherapy regimen is not feasible for majority of patients in real clinical practice. However, there is a subpopulation of patients with PDAC who long-term survivors are. Several clinical markers helping to predict patienťs prognosis are already available. Recently, number of molecular prognostic markers were described, and they will probably have an important role in future. In this article we will discuss the clinical, histopathological, and molecular prognostic markers that can be useful for the prognostic stratification.
Key words
pancreatic cancer, prognosis, markers, microRNA
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...